Archive for the ‘Bartonella’ Category

Florida Undercounts Lyme Disease & Downplays its Risk

https://www.lymedisease.org/florida-undercounts-lyme-disease/

Florida undercounts Lyme disease and downplays its risk

7/8/24

Melissa Bell, President of the Florida Lyme Disease Association, recently met with Florida Surgeon General Joseph A. Ladapo, MD, PhD, to discuss Lyme disease in their state. Their zoom call also included others from the Department of Health as well as Professor Kerry Clark from the University of North Florida.

Here is a follow-up email Melissa sent to the Dr. Ladapo, summarizing the call. This is a highly informative resource for anyone seeking to contact their local and state health officials. We thank Melissa for making this available to our readers.

The evidence is clear that Lyme disease is undercounted in Florida based on various data sources. The CDC surveillance counts place a heavy emphasis on “high incidence” states—which are primarily confined to the Northeast coast and upper Midwest United States. Doctors and patients are falsely told that there is “no Lyme in Florida” or that it is extremely rare.

Melissa Bell, President of Florida Lyme Disease Association.

As a result of this downplaying of the risk of Lyme and other tick-borne infections, people, especially parents, are less likely to take steps to prevent tick bites. Additionally, those infected are less likely to receive an early diagnosis. According to the CDC, “if left untreated, infection can spread to joints, the heart, and the nervous system.”

Due to poor awareness and training, doctors refuse to timely prescribe antibiotics for known tick bites even with symptoms and refuse to test for Lyme because they have been taught there is no Lyme in Florida. There is even less awareness regarding other tick-borne infections that are prevalent in the state, including Babesia, Ehrlichia, Anaplasma, and Bartonella.

Lyme and Bartonella infection can persist for years, despite antibiotic treatment (see studies linked above) and following:

New genetic group/species of Bartonella may be responsible for a portion of Lyme-like illness in Florida and other southern states. Standard lab tests for Bartonella will not likely identify these strains.

  • The CDC shows a 29.44% increase in reported cases in Florida comparing 2017-2019 data to 2022.
  • A 2021 CDC Study analyzing insurance data, revealed that in states the CDC considers to be “low incidence,” only 1 in 50 cases is counted, while in high incidence states 1 in 7 is counted. See also How much does the CDC undercount Lyme cases? It depends on where you live.
  • Standard lab tests for Lyme disease were developed to detect a single Borrelia strain present in the Northeast. Such lab tests fail to detect approximately half of actual cases pursuant to numerous peer reviewed studies. See Current Guidelines, Common Clinical Pitfalls, and Future Directions for Laboratory Diagnosis of Lyme Disease, United States; see also, Project Lyme. For unknown reasons, it appears as though the Florida Department of Health is not counting most CDC-positive Lyme cases. For example, in a July 2018 report (page 7), Quest Diagnostics showed an increase in Florida Lyme cases from 283 in 2015 to 501 in 2017, representing a 77% increase. In contrast, the CDC only reported 166 Florida Lyme cases in 2015 and 210 in 2017. Why are the CDC’s numbers for Florida so much lower than Quest, a single lab? In recent email correspondence, IGeneX has indicated a 48% positivity rate in Florida for 2023, which they consider high. There were 526 CDC-positive cases through IGeneX in 2023. Note that the IGeneX immunoblot has been validated by New York and other states and is covered by Medicare Part B. We do not have data for labs such as Mayo Clinic, Consolidated, ARUP, Medical Diagnostics Laboratory, Stony Brook University Medical Center, Cleveland Clinic, university and other labs which also test for Lyme disease in Florida, but we trust that the Florida Department of Health has this data available. We would appreciate transparency on these numbers.
  • Canine maps show a significant increase in incidence of Lyme disease, Ehrlichia, and Anaplasma in the state. Notably, dogs are less likely to travel out of state meaning the infections are more often locally acquired. 
    • According to the Companion Animal Parasite Council (CAPC), from 2019 – 2023, canine tick-borne infections have increased by 89.53% for Lyme disease; 100.49% for Ehrlichiosis; and 334.23% for Anaplasmosis in Florida.
    • In 2022, CAPC reported 4,284 canine cases compared to only 233 human cases reported by the CDC.
    • In 2023, CAPC reported 4,888 Lyme disease, 12,601 Ehrlichiosis, and 8,424 Anaplasmosis canine cases.
    • According to 2024 data YTD, Florida is considered moderate risk for Lyme and high risk for both Ehrlichia and Anaplasma. Notably, the Lyme incidence changed from 1/200 in 2023 to 1/100 for 2024 YTD.
    • The CAPC estimates its data represents “less than 30% of the activity in the geographic regions.” Applying this factor to the 4,284 cases in 2022, CAPC would estimate 14,280 canine cases which is >61x the human reported cases for the same year (4,284/.3 = 14,280).
  • MyLymeData statistics for “low incidence” states like Florida likewise show a large disparity between reported and actual cases. See Why Doesn’t the CDC Count Lyme Disease Cases in the South and the West? Everybody Else Does. | LymeDisease.org

The one-size-fits-all IDSA treatment guidelines fail countless patients, particularly those who are not timely diagnosed/treated or present with co-infections such as Babesia, Bartonella, or rickettsial infections.

  • A significant percentage of patients suffer persistent symptoms after antibiotic treatment. The CDC previously estimated 10-20% of patients, but now they claim “following antibiotic treatment, about 5-10% of people with Lyme disease have prolonged symptoms of fatigue, body aches, or difficulty thinking as a result of their infection.” We are unaware of any rationale or scientific basis for this change. To the contrary, research demonstrates a higher percentage. See e.g. Post-treatment Lyme disease syndrome symptomatology and the impact on life functioning: is there something here? (at six months, 36% of patients reported new-onset fatigue, 20% widespread pain, and 45% neurocognitive difficulties). It is widely accepted that patients who are not timely diagnosed and treated are more likely to suffer from persistent symptoms after IDSA-recommended treatment.
  • Lyme persists due to biofilms, round bodies, inability of antibiotics to penetrate tissues/organs. See Lyme Persists
  • Studies at Johns Hopkins showed doxycycline failed to eradicate the Lyme bacteria Borrelia burgdorferi in vitro. However, triple antibiotic combinations were effective in a mouse model. See also Superior efficacy of combination antibiotic therapy versus monotherapy in a mouse model of Lyme disease
  • Studies showing “long term antibiotics are not effective” used a single antibiotic, did not have a true placebo (i.e. giving IV rocephin to the control group), and/or ignored improvement of symptoms such as fatigue. Studies were designed to fail and then were widely reported without mention of study limitations/flaws.

The failure to timely diagnose and adequately treat Lyme disease comes at a tremendous economic burden. Lyme patients had 87% more visits to the doctor and 71% more visits to the emergency room within the year following diagnosis. This does not take into account additional economic costs due to missed work and long term disability. See Johns Hopkins study Lyme Disease Costs Up to $1.3 Billion Per Year to Treat, Study Finds and Health Care Costs, Utilization and Patterns of Care following Lyme Disease | PLOS ONE; see also The Financial Implications of a Well-Hidden and Ignored Chronic Lyme Disease Pandemic – PMC

Requested Action Items:

  1. Transparency on CDC positive cases. What are the reported case counts for each of the labs who test for Lyme disease in Florida and what percent are being reported to the CDC? Why are such a large percentage of cases not being counted? Why are canine cases an estimated 61x higher than human cases?
  2. Mandated education of clinicians in the state and alerts to medical care providers advising of increase in cases of Lyme, Ehrlichia, and Anaplasma in the state. Babesia and Bartonella can also cause overlapping symptoms. There are free CME webinars available on Invisible International.
  3. Educate residents about the risk of tick bites, including education of children in schools. See e.g. A School-Based Intervention to Increase Lyme Disease Preventive Measures Among Elementary School-Aged Children
  4. Since 2017, Babesia has been reportable in Florida. Please share the reports.
  5. Similar to the federal Tick-Borne Disease Working Group, we request that a Florida task force be formed, composed of members who have a diversity of backgrounds and perspectives (i.e. patients, researchers, health practitioners, public health).
  6. Explore potential legislation in the state promoting tick-borne disease awareness, mandating insurance coverage outside of IDSA guidelines when deemed medically necessary, and protecting doctors who prescribe medications in accordance with the ILADS standard of care. See Reviewing Current Lyme Legislation
  7. Fund research within the state, including widespread tick testing and patient-centered studies (i.e. efficacy of emerging combination therapies, screening of at-risk pregnant women, etc.).
  8. Update Florida Department of Health website on Lyme disease. In particular (but not limited to):
    • The FL DOH page discussing Lyme rashes under the symptoms and treatment tab is outdated and inconsistent with the CDC website. It is critical to communicate that there are many forms of erythema migrans rashes, not just the classic bull’s-eye. The current page states “between 60 and 80% of people will develop a red, “bull’s-eye rash” which is not accurate. In this study, researchers discovered most rashes were uniform in color (51%), pink (74%), oval (63%), and with clear borders (92%). Only 6% had the classic bull’s-eye pattern.
    • Under the symptoms and treatment tab, it states “a few patients, especially those diagnosed in the later stages of disease, may have persistent or recurrent symptoms.” (emphasis added). For many years, the  CDC had recognized that 10-20% of patients continue to suffer symptoms after antibiotic treatment. Without explanation, the CDC recently changed this estimate to 5-10% without any clear rationale for the change. Research from Johns Hopkins demonstrates a higher percentage than the CDC. See e.g. Post-treatment Lyme disease syndrome symptomatology and the impact on life functioning: is there something here? (at six months, 36% of patients reported new-onset fatigue, 20% widespread pain, and 45% neurocognitive difficulties); see also Health Care Costs, Utilization and Patterns of Care following Lyme Disease | PLOS ONE (“over 63% of the Lyme disease cases had at least one diagnosis associated with PTLDS, which is 36 percentage points higher a rate than the prevalence of the same symptoms in our control population”). Whatever estimate is used, it is certainly more than “a few.”
    • Under the transmission tab of the FL DOH website, it states “studies have shown that both nymph and adult ticks need to be attached for more than 24 hours to effectively transmit the infection.” However, a literature review has determined that in animal models, transmission can occur in less than 16 hours, and the minimum attachment time for transmission of infection has never been established. See Lyme borreliosis: a review of data on transmission time after tick attachment – PMC. In particular, if a tick is only partially fed and then attaches to a human, spirochetes can be found in the salivary glands increasing the risk of disease transmission after shorter attachment periods. Additionally, if a tick is not removed properly (i.e. if the body is squeezed or if heat or oils are used), then this increases the risk of disease transmission.
    • There is a growing body of research showing that ticks can also spread Bartonella infections to humans. See Can Ticks Transmit Bartonella? – Project Lyme.
    • Include acknowledgement that Lyme can spread from mother to baby during pregnancy. See e.g., CDC “Untreated Lyme disease during pregnancy can lead to infection of the placenta; spread from mother to fetus is possible but extremely rare.” While we disagree with the term “extremely rare” absent scientific studies proving this point, at least the CDC is now publicly acknowledging maternal-fetal transmission. See also Congenital Lyme disease is under-recognized by medical professionals (50% of Lymelight grant recipients were born with Lyme disease); Ongoing study Pregnancy and Early Neurodevelopmental Outcomes Following In Utero Lyme Disease Exposure funded by the Clinical Trials Network for Lyme and other Tick-borne Diseases (CTN); Lyme Disease and Pregnancy – LYMEHOPE
    • Provide an acknowledgement that existing laboratory tests for Lyme disease often result in false negative results such as: “if you are tested for Lyme disease and the results are negative, this does not necessarily mean you do not have Lyme disease. If you continue to experience unexplained symptoms, you should contact your health care provider and inquire about the appropriateness of retesting or initial or additional treatment.” See e.g., Maryland legislation.
    • Provide links to both the ILADS and IDSA standards of care for treating Lyme disease and related infections. See Schools of Thought about Lyme Disease

Melissa Bell, Esq. founded the Florida Lyme Disease Association in 2013, after several members of her family were severely impacted by Lyme disease. She also serves on the Executive Board of Project Lyme.

_______________

Great article!  

For more:

The take home: Clark is finding borrelia (Lyme) strains in the South that the current CDC two-tier testing will never pick up in a thousand years.

https://www.researchgate.net/publication/285584725_Isolation_of_live_Borrelia_burgdorferi_sensu_lato_spirochetes_from_patients_with_undefined_disorders_and_symptoms_not_typical_for_Lyme_diseases

The take home: Clark found live Bbsl (bissettii-like strain) in people from the Southeast who had undefined disorders not typical of LD, and were treated for LD even though they were seronegative, proving that B. bissetti is responsible for worldwide human infection.

He also showed DNA of Bbsl in Lone Star ticks which might be a bridge vector of transmission to humans.

Dr. Clark was the first to report finding LD spirochetes in animals and ticks in South Carolina, as well as in wild lizards in South Carolina and Florida. He has documented the presence of LD Borrelia  species, Babesia microti, Anaplasma phagocytophilumRickettsia species, and other tick-borne pathogens in wild animals, ticks, dogs, and humans in Florida and other southern states.

Ross Lyme & Tick-borne Diseases Protocol Version 4

https://www.treatlyme.net/lyme-disease-treatment-guidelines

About The Ross Lyme & Tick-borne Diseases Protocol—Version 4

New in Version 4

The Ross Lyme & Tick-borne Diseases Protocol–Version 4 update, released 6/17/24, has a number of significant changes.

Name change. In Version 4, I have updated our name to include “tick-borne”. This recognizes that people can have Bartonella, Babesia, or other tick-borne diseases, separate from having Lyme (Borrelia) infection.

But there are more significant updates than our name change. Version 4

  • Emphasizes plant-based foods recommendations in Part 2. Diet;
  • Promotes healthy intestinal microbiome—even on antibiotics with a new Part 3. Healthy Intestinal Microbiome; and
  • Includes an herbal antibiotic only option to treat the three Bs (Borrelia, Bartonella, and Babesia) simultaneously in Part 12. Lyme Infection and Part 13. Bartonella & Babesia Infections.
  • Moves lifestyle, and related areas, of sleep, diet, healthy intestinal microbiome, and exercise to the front of the protocol to emphasize the key role these areas have in recovery.

Introduction

These are support and treatment guidelines to treat chronic Lyme or tick-borne infections. This protocol addresses most problems that keep a person from getting well. It is more comprehensive than the antibiotic focused Infectious Disease Society of America (IDSA)International Lyme and Associated Disease Society (ILADS), and United States Centers for Disease Control and Prevention guidelines. While herbal and prescription antibiotics may decrease the germ load in chronic Lyme and tick-borne infections, they often do not correct the underlying problems that cause ongoing symptoms.

The Ross Lyme Support Protocol includes essential steps for the beginning and throughout a chronic Lyme disease or tick-borne infection treatment. It is designed to:

  • boost the immune system,
  • improve detoxification,
  • speed recovery,
  • kill the infections, and
  • protect and repair from the harmful effects of the infections and the herbal or prescription antibiotics.

While the following Lyme disease and tick-borne infection treatment approach focuses on a limited number of areas, it may correct most of the problems like:

  • low energy,
  • pain,
  • insomnia,
  • brain, neurologic, and thinking problems (brain fog), and
  • immune compromise and suppression.

Herxheimer Reactions. When a person starts a Lyme disease or tick-borne infection treatment or changes herbal and prescription antibiotics, it is common to experience some worsening in symptoms. See Herxheimer Die-off Reaction: Inflammation Run Amok for more information about this and the steps you can take to treat it.

Treatment Length and Persistence. Generally, it takes a minimum of six months to see if these supports and treatments will help. Supplements can speed recovery, but treating Lyme still takes time. Once you have marked improvement, then you can likely stop many of these nutritional supports except for probiotics, curcumin, ashwagandha, and a good multivitamin. See Getting Healthy: Will I? When? How Do I? for more information about Lyme disease and tick-borne infection treatment length and persistence.

About Supplements. Throughout this protocol I include supplements as nutritional supports based on their known functions. Basic research and my clinical experience show they may help the various symptoms and problems in Lyme disease and tick-borne infections.  (See link for article)

_______________

**Comment**

Lots of great info here.

For more:

The Mind Blowing Truth About Bartonella: Dr. Ed Breitschwerdt

http://

The Mind Blowing Truth About Bartonella Most Doctors Don’t Know

Dive into the complex world of Bartonella with Dr. Ed Breitschwerdt, a leading veterinary researcher. Unravel the challenges of diagnosing this elusive bacteria, from understanding its diverse transmission vectors to exploring advanced detection methods like digital PCR. Gain insights into the pathophysiology of chronic Bartonella infections and its potential neuropsychiatric manifestations through intriguing case studies. Discover the intricate interplay between acute and chronic phases, antibody production, and the prevalence of different strains that can impact test results. Don’t miss this opportunity to elevate your expertise in managing Bartonella and its intricate implications for human health.

Chapters

00:00 Introduction and Background

00:42 Interest in Bartonella Research

05:38 Challenges and Unique Aspects of Bartonella

08:37 Transmission of Bartonella

11:11 Vectors and Transmission to Humans

14:58 Prevalence of Bartonella and Challenges in Diagnosis

29:35 Chronic Bartonella Infection and Recrudescence

32:20 Pathophysiology of Chronic Bartonella Infection

36:06 Diagnostic Challenges and Digital PCR

41:13 Challenges in Accurate Diagnosis

42:02 Different Results from Different Labs

42:16 Different Isolates of the Organism

43:42 Prevalence of Bartonella Henselae Strains

44:41 Patients Stop Making Antibodies

45:56 Interplay Between Acute and Chronic Infections

46:45 Serofast State in Bartonella Henselae

47:21 Exposure to Bartonella Species

48:19 Testing Blood Donors for Bartonella

49:47 Role of Bartonella in Neurologic Diseases

52:43 Symptoms of Bartonella Infection

54:03 Understanding Bartonella on a Cellular Basis

57:34 Developing a Diagnostic Test for Bartonella

01:00:09 Vaccine Target for Bartonella

01:11:44 Protecting the Human-Animal Bond

01:18:03 Future Goals: Diagnostic Test and Vaccine

Learn more about my guest: Dr. Ed Breitschwerdt, DVM , DACVIM Learn more about Dr. Breitschwerdt and his work at NC State University- https://globalhealth.cvm.ncsu.edu/fac…

Learn more about Dr. Breitschwerdt’s work at Galaxy Diagnostics- https://www.galaxydx.com/

Donate to the NC State Bartonella/Vector Borne Research Fund- https://securelb.imodules.com/s/1209/…

For more:

Post-COVID Reactivation of Latent Bartonella: A Case Report & Literature Review

https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-024-09336-7

Case Report

Open access

Published: 

Post-COVID reactivation of latent Bartonella henselae infection: a case report and literature review

Yanzhao DongAhmad AlhaskawiXiaodi ZouHaiying ZhouSohaib Hasan Abdullah EzziVishnu Goutham KotaMohamed Hasan Abdulla Hasan AbdullaAlenikova OlgaSahar Ahmed Abdalbary & Hui Lu

Abstract

Cat scratch disease (CSD) is caused by Bartonella henselae (B. henselae) and presents as lymphadenopathy following close contact with cats. However, in context of the global COVID-19 pandemic, clinical manifestations of CSD may vary, posing new challenges for healthcare professionals. Here we describe a case of a 54-year-old male with painful left upper arm mass, which gradually resolved until he was infected with COVID-19. The mass then rapidly progressed before admission. Meanwhile, pulmonary symptoms including pleural effusion emerged simultaneously. The cause was undetermined with routine blood culture and pathological test until the next generation sequencing (NGS) confirmed the presence of B. henselae. We believe this case is the first to report localized aggravation of CSD after COVID-19 infection and hopefully, offers treatment experience for clinicians worldwide.

_______________

**Comment**

On a personal note: both my husband and I required Bartonella treatment for a relapse after COVID.  What the abstract does not mention is if this patient received the mRNA gene therapy shot which would complicate matters even more. Since his presentation was in January of 2023, he very well could have had multiple shots.

While the case report was about a severe Bartonella manifestation, please know Bartonella can present a million different ways.  Please read:  https://madisonarealymesupportgroup.com/2019/04/24/human-bartonellosis-an-underappreciated-public-health-problem/

For more:

Antibodies to Borrelia Burgdorferi and Bartonella Species in Serum and synovial fluid From People With Rheumatic Diseases

https://www.researchgate.net/publication/378974250_Antibodies_to_Borrelia_burgdorferi_and_Bartonella_species_in_serum_and_synovial_fluid_from_people_with_rheumatic_diseases

Antibodies to Borrelia burgdorferi and Bartonella species in serum and synovial fluid from people with rheumatic diseases

Authors:

Abstract and Figures

Vector-borne infections may underlie some rheumatic diseases, particularly in people with joint effusions. This study aimed to compare serum and synovial fluid antibodies to B. burgdorferi and Bartonella spp. in patients with rheumatic diseases. This observational, cross-sectional study examined paired synovial fluid and serum specimens collected from 110 patients with joint effusion between October 2017 and January 2022. Testing for antibodies to B. burgdorferi (using CDC criteria) and Bartonella spp. via two indirect fluorescent antibody (IFA) assays was performed as part of routine patient care at the Institute for Specialized Medicine (San Diego, CA, USA). There were 30 participants (27%) with positive two-tier B. burgdorferi serology and 26 participants (24%) with IFA seroreactivity (≥1:256) to B. henselae and/or B. quintana. Both B. burgdorferi IgM and IgG were detected more frequently in synovial fluid than serum: 27% of patients were either IgM or IgG positive in synovial fluid, compared to 15.5% in serum (P = 0.048). Conversely, B. henselae and B. quintana antibodies were detected more frequently in serum than synovial fluid; overall only 2% of patients had positive IFA titers in synovial fluid, compared to 24% who had positive IFA titers in serum (P < 0.001). There were no significant associations between B. burgdorferi or Bartonella spp. seroreactivity with any of the clinical rheumatological diagnoses. This study provides preliminary support for the importance of synovial fluid antibody testing for documenting exposure to B. burgdorferi but not for documenting exposure to Bartonella spp.
IMPORTANCE This study focuses on diagnostic testing for two common vector-borne diseases in an affected patient population. In it, we provide data showing that antibodies to B. burgdorferi, but not Bartonella spp., are more commonly found in synovial fluid than serum of patients with joint effusion. Since Lyme arthritis is a common—and sometimes difficult to diagnose—rheumatic disease, improving diagnostic capabilities is of utmost importance. While our findings are certainly not definitive for changes to practice, they do suggest that synovial fluid could be a useful sample for the clinical diagnosis of Lyme disease, and future prospective studies evaluating this claim are warranted.
For more: